SU-FF-T-132: CT-Based Intra-Cavitary High Dose Rate (HDR) Brachytherapy for Cervical Cancer: Planning and QA

2007 ◽  
Vol 34 (6Part9) ◽  
pp. 2431-2431
Author(s):  
B Wang ◽  
Y Zhu ◽  
I Yeo ◽  
A Kwon ◽  
C Henson
Keyword(s):  
Cervical Cancer ◽  
Dose Rate ◽  
High Dose Rate ◽  
High Dose ◽  
Hdr Brachytherapy

Outcomes for High-Dose-Rate (HDR) Brachytherapy in the Treatment of Cervical Cancer

2013 ◽  
Vol 87 (2) ◽  
pp. S406
Author(s):  
M. Chin ◽  
C. Min ◽  
R. Sethi ◽  
S.C. Formenti ◽  
G. Jozsef ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Dose Rate ◽  
High Dose Rate ◽  
High Dose ◽  
Hdr Brachytherapy

Balloon pneumo-occluder for vaginal distension at the time of high dose rate (HDR) brachytherapy in patients with cervical cancer

2017 ◽  
Vol 145 ◽  
pp. 187
Author(s):  
A.M. Rolston ◽  
P. Soni ◽  
R.K. Reynolds ◽  
J. Prisciandaro ◽  
K. McLean ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Dose Rate ◽  
High Dose Rate ◽  
High Dose ◽  
Hdr Brachytherapy ◽  
Vaginal Distension

scholarly journals Outcomes of patients with cervical cancer treated with low- or high-dose rate brachytherapy after concurrent chemoradiation

2021 ◽  
pp. ijgc-2020-002120
Author(s):  
Aba Anoa Scott ◽  
Joel Yarney ◽  
Verna Vanderpuye ◽  
Charles Akoto Aidoo ◽  
Mervin Agyeman ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Overall Survival ◽  
Dose Rate ◽  
Local Control ◽  
Disease Free Survival ◽  
High Dose Rate ◽  
High Dose ◽  
Hdr Brachytherapy ◽  
Free Survival ◽  
Disease Free

ObjectiveThe majority of patients with cervical cancer in Ghana present with locally advanced disease. In October 2014, high-dose rate (HDR) brachytherapy was introduced at the National Center for Radiotherapy, Accra after years of using low-dose rate (LDR) brachytherapy. The aim of this study was to compare the treatment outcomes of patients treated with LDR versus HDR brachytherapy.MethodsPatients with cervical cancer treated from January 2008 to December 2017 were reviewed. Those with stage IB–IIIB who received chemoradiation plus brachytherapy were included in the study. Post-operative patients and those with stage IV were excluded. The study end points were local control, disease-free survival, and overall survival at 2 years. Endpoints were estimated using the Kaplan–Meier method. Comparisons between treatment groups were performed using the log-rank test and Cox proportional hazards model.ResultsWe included 284 LDR and 136 HDR brachytherapy patients. For stages IB, IIA, IIB, IIIA and IIIB disease, the 2-year local control for LDR versus HDR brachytherapy was 63% and 61% (p=0.35), 86% and 90% (p=0.68), 86% and 88% (p=0.83), 66% and 60% (p=0.56), and 77% and 40% (p=0.005), respectively. The 2-year disease-free survival for LDR versus HDR brachytherapy was 64% and 61% (p=0.50), 81% and 69% (p=0.18), 81% and 80% (p=0.54), 62% and 33% (p=0.82), and 71% and 30% (p=0.001) for stages IB, IIA, IIB, IIIA, and IIIB, respectively. The 2-year overall survival for LDR versus HDR brachytherapy was 94% and 93% (p=0.92), 98% and 68% (p=0.21), 89% and 88% (p=0.60), and 88% and 82% (p=0.34) for stages IB, IIA, IIB, and IIIB disease, respectively.ConclusionThere was no difference between LDR and HDR brachytherapy in local control and disease-free survival for all stages of disease, except in stage IIIB. These findings highlight the need to refine this brachytherapy technique for this group of patients.

Sign in / Sign up

Export Citation Format

Share Document